Targeted vectors for cancer immunotherapy
AssigneeUniversity of Southern California
InventorsErlinda M. Gordon, Frederick L. Hall
Life of this patent
Estimating the term…
Abstract
This invention provides compositions and methods for treating cancer. More specifically this invention is directed to a targeted retroviral vector comprising a cytokine gene that can be administered either alone or in combination with a targeted retroviral vector comprising a cytocidal gene for treating cancer in a subject. Also provided are a kit or drug delivery system comprising the compositions for use in the methods described.
Claims6
A pharmaceutical composition comprising a targeted retroviral vector particle comprising a modified viral surface protein comprising a collagen binding motif obtained from von Willebrand coagulation factor for targeting the vector, and an immunostimulatory cytokine gene, and a second targeted retroviral vector particle comprising a modified viral surface protein comprising a collagen binding motif obtained from von Willebrand coagulation factor for targeting the second vector and a cytocidal gene, wherein the cytocidal gene is thymidine kinase and the immunostimulatory cytokine is GM-CSF, and wherein the titer of the retroviral particle for each vector is lower than if each vector is used alone.
A composition comprising a targeted retroviral vector particle comprising a modified viral surface protein comprising a collagen binding motif obtained from von Willebrand coagulation factor for targeting the vector and an immunostimulatory cytokine gene and a targeted retroviral vector particle comprising a modified viral surface protein comprising a collagen binding motif obtained from von Willebrand coagulation factor for targeting the vector and a cytocidal gene, wherein the cytocidal gene is thymidine kinase and the immunostimulatory cytokine is GM-CSF, and wherein the titer of the retroviral particle for each vector is lower than if each vector is used alone.
Dependencies are inferred from the claim text.